RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)

YILMAZ, Fatma; ALBAYRAK, Murat; ARAS, Merih REİS; MARAL, Senem; AFACAN ÖZTÜRK, Hacer Berna; TIĞLIOĞLU, Pınar; TIĞLIOĞLU, Mesut; SAĞLAM, Buğra

doi:10.1016/j.htct.2021.10.1057

Hematology, Transfusion and Cell Therapy

ISSN: 2531-1379

Hematology, Transfusion and Cell Therapy is a quarterly scientific publication of the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), Associazione Italo-Brasiliana di Ematologia (AIBE), Eurasian Hematology Oncology Group (EHOG), and Sociedade Brasileira de Oncologia Pediátrica (SOBOPE).

Hematology, Transfusion and Cell Therapy publishes original articles, review articles and case reports covering various areas in the field of hematology and hemotherapy. The journal was previously published, until 2016, as Revista Brasileira de Hematologia e Hemoterapia.

ISSN print: 2531-1379
ISSN online: 2531-1387

Published by Elsevier Editora Ltda, Rio de Janeiro, Brazil.

Indexed in:

Web of Science, LILACS, SciELO Brazil, ESCI (Web of Science), Scopus, and PubMed/PMC

One of the causes of autoimmune hemolytic anemia is drugs. Vaccination is the most important step in the management of the COVID-19 pandemic. After receiving the m-RNA COVID-19 (Pfizer-BioNTech) vaccine, the patient admitted with weakness and jaundice for the last three days. Laboratory results are consistent with AIHA recurrence. Splenectomy was performed after the patient stabilized with rituximab therapy. Especially newly developed therapeutic agents have a potential risk of new side effects.

Full text is only aviable in PDF

Indexed in:

Follow us:

Subscribe to our newsletter